Louise China News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mar 5, 2021
ATTIRE and CONFIRM trials may not change practice, but are still important
Two approaches to managing patients with cirrhosis, either decompensated or type 1 hepatorenal syndrome (HRS-1), turned in mostly disappointing results, according to findings from a pair of phase III trials.
In hospitalized patients with decompensated cirrhosis, albumin infusions to boost the albumin level to a target of ≥30 g/L was not more beneficial than the current U.K. standard of care, described in a 2018 trial outline, reported Louise China, PhD, of University College London, and ATTIRE co-authors.
In the second study, terlipressin was more effective than placebo for improving renal function in adults with cirrhosis and HRS-1, but the treatment was tied to serious adverse events (AEs), including respiratory failure, wrote Florence Wong, MBBS, MD, of the University of Toronto, and CONFIRM co-authors. ....

New Haven , United States , West Haven , Shalmali Pal , Guadalupe Garcia Tsao , Florence Wong , University College London , University Of Toronto , Mallinckrodt Pharmaceuticals , Yale School Of Medicine , Rerring Pharmaceuticals , Veterans Affairs Connecticut Healthcare System , Louise China , New England Journal , Yale School , Contributing Writer , Health Innovation Challenge , புதியது புகலிடம் , ஒன்றுபட்டது மாநிலங்களில் , மேற்கு புகலிடம் , குவாடலூப் கார்சியா ட்‌ஸ்ம் , புளோரன்ஸ் வோங் , பல்கலைக்கழகம் கல்லூரி லண்டன் , பல்கலைக்கழகம் ஆஃப் டொராண்டோ , யேல் பள்ளி ஆஃப் மருந்து , வீரர்கள் வாழ்க்கைத்தொழில்கள் கனெக்டிகட் சுகாதாரம் அமைப்பு ,